INTRODUCTION {#sec1}
============

Nosocomial infections caused by Gram-negative bacteria are increasingly difficult to treat due to the global spread of multidrug-resistant (MDR) strains which are resistant to several antibiotics, such as carbapenems, cephalosporins, aminoglycosides, and quinolones ([@B1]). The WHO has listed carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii as the pathogens against which urgent development of new antibiotics are needed, since the emergence of these resistant pathogens poses serious public health issues due to the limited number of treatment options ([@B2], [@B3]).

Since the 1980s, numerous attempts to conjugate iron-binding functional groups onto β-lactams have been made to hijack the iron uptake systems of Gram-negative bacteria and circumvent the outer membrane barriers ([@B4][@B5][@B6]). However, none of the molecules have been approved for clinical use for various reasons, such as a lack of correlation between *in vitro* and *in vivo* efficacies ([@B7][@B8][@B9]). Cefiderocol (CFDC; S-649266), a novel catechol-substituted siderophore cephalosporin, is structurally different from other recently developed hydroxypyridone-substituted siderophore monobactam antibiotics such as BAL30072, MB-1, and MC-1 and has been reported to have potent antibacterial activity against MDR Gram-negative pathogens, including carbapenem-resistant strains of Enterobacteriaceae, P. aeruginosa, and A. baumannii, as well as potent *in vivo* efficacy against multiple clinical strains of Gram-negative bacteria in mouse lung infection models ([@B10][@B11][@B14], [@B34]; I. Ghazi, M. L. Monogue, M. Tsuji, and D. P. Nicolau, submitted for publication). This is the first report evaluating the *in vitro* features of cefiderocol, including its antibacterial spectrum against Gram-negative and Gram-positive bacteria and its mode of action, such as penicillin-binding protein (PBP) binding affinity and morphological changes, as well as the impacts of various β-lactamases, efflux pump overexpression, and deficiency of porin or iron transporter on the *in vitro* activity.

RESULTS {#sec2}
=======

Antibacterial activity against Gram-negative and Gram-positive bacteria. {#sec2-1}
------------------------------------------------------------------------

The MICs of cefiderocol were ≤2 μg/ml against a broad range of Gram-negative bacterial strains, including Enterobacteriaceae such as Enterobacter spp., Escherichia coli, Klebsiella spp., Proteus spp., Providencia spp., Salmonella spp., and Yersinia spp., as well as Vibrio species ([Table 1](#T1){ref-type="table"}). Cefiderocol showed *in vitro* activity against nonfermenting bacteria such as Acinetobacter spp., Pseudomonas spp., and Burkholderia spp.; cefiderocol also showed *in vitro* activity against the intrinsically MDR bacteria of Stenotrophomonas maltophilia and Elizabethkingia meningoseptica, as well as the causative pathogens for respiratory tract infections, such as Haemophilus spp., Moraxella catarrhalis, and Bordetella parapertussis. On the other hand, the MICs of cefiderocol against Campylobacter jejuni ATCC 33560 and 794009 as well as ceftriaxone-resistant Neisseria gonorrhoeae 868339 were relatively high (MIC, \>4 μg/ml) for the Gram-negative bacteria tested, although the MICs of cefiderocol against two other N. gonorrhoeae strains, including an azithromycin-resistant strain, were ≤0.5 μg/ml. The MICs of cefiderocol against aerobic Gram-positive bacteria growing in an aerobic or microaerophilic atmosphere were ≥4 μg/ml, except for those against Streptococcus pneumoniae ATCC 49619, Streptococcus pyogenes ATCC 10389, and Micrococcus luteus ATCC 9341, which were 2, 1, and 4 μg/ml, respectively. The activities against these strains of Gram-positive bacteria were weaker than those of other tested β-lactam compounds. The MICs of cefiderocol against anaerobic Gram-negative and Gram-positive bacteria showed variation within genera and were higher than those of cefepime or meropenem, with cefiderocol MICs of 0.5 to \>32 μg/ml, except for that against Fusobacterium necrophorum, which was ≤0.031 μg/ml ([Table 2](#T2){ref-type="table"}). Although cefiderocol showed activity against some ATCC strains of Bacteroides spp., Prevotella spp., and Clostridium spp., with MICs of 1 to 2 μg/ml, cefiderocol did not show potent activity against multiple clinical isolates of Bacteroides spp., Prevotella spp., or Clostridium difficile, of which the MIC~50~s were 32 μg/ml or higher ([Table 3](#T3){ref-type="table"}).

###### 

MICs of cefiderocol and other antibiotics against Gram-negative and Gram-positive bacteria

  Organism                                                        Strain       MIC (μg/ml)[^*f*^](#T1F6){ref-type="table-fn"}                                                                         
  --------------------------------------------------------------- ------------ ------------------------------------------------ -------- -------- -------- -------- -------- -------- -------- ------ --------
  Gram-negative bacteria                                                                                                                                                                              
      Acinetobacter baumannii                                     ATCC 19606   0.063                                            8        16       1        16       16       2        0.5      16     1
      Acinetobacter calcoaceticus                                 ATCC 23055   0.063                                            0.125    0.063    ≤0.031   ≤0.031   0.063    ≤0.031   0.25     0.25   ≤0.031
      Acinetobacter haemolyticus                                  ATCC 17906   ≤0.031                                           2        1        0.25     ≤0.031   4        ≤0.031   1        \>32   0.125
      Acinetobacter johnsonii                                     ATCC 17909   0.125                                            8        2        0.25     ≤0.031   16       ≤0.031   0.25     1      0.25
      Acinetobacter lwoffii                                       ATCC 15309   ≤0.031                                           1        0.25     0.063    ≤0.031   2        ≤0.031   0.125    0.5    0.25
      Aeromonas hydrophila                                        IFO3820      0.125                                            0.5      0.063    2        4        0.25     1        \>32     2      ≤0.031
      Bordetella parapertussis                                    NCTC 5952    1                                                1        1        ≤0.031   ≤0.031   0.5      1        ≤0.031   2      ≤0.031
      Burkholderia cepacia                                        ATCC 25416   ≤0.031                                           4        32       4        32       2        2        \>32     \>32   1
      Burkholderia multivorans                                    SR01869      2                                                2        32       4        \>32     2        4        \>32     \>32   4
      Campylobacter jejuni                                        ATCC 33560   \>4                                              \>16     2        0.015    64       4        NT       NT       NT     0.25
      Campylobacter jejuni                                        794009       \>4                                              \>16     2        0.015    64       4        NT       NT       NT     \>4
      Citrobacter freundii                                        ATCC 8090    0.063                                            1        ≤0.031   ≤0.031   1        0.125    0.25     0.5      2      ≤0.031
      Elizabethkingia meningoseptica                              NCTC 10016   1                                                \>32     \>32     16       \>32     \>32     \>32     \>32     32     8
      Enterobacter aerogenes                                      ATCC 13048   ≤0.031                                           1        0.063    0.063    4        0.5      0.5      0.25     2      ≤0.031
      Enterobacter cloacae                                        ATCC 13047   0.5                                              8        0.125    0.063    16       0.5      8        \>32     2      ≤0.031
      Enterobacter cloacae[^*a*^](#T1F1){ref-type="table-fn"}     NCTC 13464   0.125                                            2        8        0.063    2        0.25     0.5      0.25     2      ≤0.031
      Escherichia coli                                            ATCC 25922   0.125                                            0.5      0.125    ≤0.031   2        0.5      0.25     0.5      1      ≤0.031
      Escherichia coli                                            ATCC 35218   ≤0.031                                           0.25     0.125    ≤0.031   1        0.125    0.25     0.5      2      ≤0.031
      Escherichia coli[^*a*^](#T1F1){ref-type="table-fn"}         NCTC 13462   2                                                8        \>32     ≤0.031   2        1        2        0.25     4      0.25
      Haemophilus influenzae                                      ATCC 10211   0.25                                             0.063    ≤0.031   0.063    ≤0.031   ≤0.031   0.125    0.25     8      ≤0.031
      Haemophilus influenzae                                      ATCC 49247   2                                                0.5      1        0.125    0.125    0.125    1        0.25     8      ≤0.031
      Haemophilus parainfluenzae                                  ATCC 7901    0.25                                             ≤0.031   ≤0.031   ≤0.031   ≤0.031   ≤0.031   ≤0.031   0.25     1      ≤0.031
      Klebsiella oxytoca                                          ATCC 13182   0.063                                            0.25     0.125    0.063    4        0.5      0.5      0.25     2      0.063
      Klebsiella pneumoniae                                       ATCC 43816   ≤0.031                                           0.125    0.063    0.063    2        0.25     0.25     0.25     1      0.063
      Moraxella catarrhalis                                       ATCC 25238   ≤0.031                                           0.063    0.125    ≤0.031   ≤0.031   0.063    ≤0.031   1        0.5    ≤0.031
      Morganella morgannii                                        ATCC 25830   ≤0.031                                           0.125    0.063    0.125    ≤0.031   0.063    0.125    \>32     1      ≤0.031
      Neisseria gonorrhoeae                                       ATCC 49226   0.5                                              0.12     0.12     0.03     ≤0.25    0.12     NT       NT       NT     0.004
      Neisseria gonorrhoeae[^*b*^](#T1F2){ref-type="table-fn"}    867807       0.25                                             0.12     0.06     0.015    ≤0.25    0.12     NT       NT       NT     0.008
      Neisseria gonorrhoeae[^*c*^](#T1F3){ref-type="table-fn"}    868339       \>4                                              \>16     \>8      0.06     1        \>16     NT       NT       NT     \>4
      Neisseria meningitidis                                      ATCC 13077   0.125                                            0.063    ≤0.031   ≤0.031   ≤0.031   ≤0.031   ≤0.031   \>32     8      ≤0.031
      Proteus mirabilis                                           ATCC 29906   ≤0.031                                           0.25     0.125    0.125    0.5      0.125    0.5      \>32     4      ≤0.031
      Proteus vulgaris                                            ATCC 13315   ≤0.031                                           0.125    0.063    0.125    ≤0.031   0.063    0.25     32       0.5    ≤0.031
      Providencia alcalifaciens                                   ATCC 9886    ≤0.031                                           0.25     0.063    0.063    2        0.25     0.125    \>32     4      ≤0.031
      Providencia rettgeri                                        ATCC 29944   ≤0.031                                           0.25     1        0.063    4        0.25     \>32     \>32     0.5    ≤0.031
      Providencia stuartii                                        ATCC 29914   ≤0.031                                           0.25     0.063    0.125    1        0.5      0.25     \>32     0.5    ≤0.031
      Pseudomonas aeruginosa                                      ATCC 27853   0.5                                              2        2        0.25     2        2        0.5      0.5      4      0.25
      Pseudomonas aeruginosa[^*d*^](#T1F4){ref-type="table-fn"}   NCTC 13437   0.5                                              \>32     \>32     \>32     \>32     \>32     \>32     1        32     32
      Pseudomonas putida                                          ATCC 12633   0.125                                            2        2        1        8        2        0.5      0.5      0.5    0.063
      Pseudomonas stutzerii                                       ATCC 11607   0.125                                            0.5      0.125    0.125    2        0.5      0.125    0.125    0.5    ≤0.031
      Salmonella enterica serovar Choleraesuis                    ATCC 51741   0.015                                            0.5      0.06     0.03     4        0.5      NT       NT       NT     0.03
      Salmonella enterica serovar Enteritidis                     G-14         0.25                                             1        0.063    ≤0.031   2        0.5      1        1        16     ≤0.031
      Salmonella enterica serovar Paratyphi                       598989       0.06                                             0.5      0.06     0.03     4        0.25     NT       NT       NT     \>4
      Salmonella enterica serovar Typhi                           673937       0.015                                            0.5      0.12     0.03     2        0.25     NT       NT       NT     \>4
      Salmonella enterica serovar Typhimurium                     ATCC 13311   ≤0.031                                           0.5      0.063    ≤0.031   4        0.5      0.5      0.5      2      ≤0.031
      Serratia marcescens                                         ATCC 13880   ≤0.031                                           0.5      0.25     0.063    2        1        0.5      \>32     1      0.063
      Shigella flexneri[^*e*^](#T1F5){ref-type="table-fn"}        705927       0.5                                              0.06     0.25     0.03     2        0.06     NT       NT       NT     0.015
      Stenotrophomonas maltophilia                                ATCC 13637   0.125                                            32       \>32     \>32     \>32     32       32       1        4      0.25
      Vibrio fluvialis                                            NCTC 11327   0.25                                             0.25     0.25     0.25     4        0.5      4        0.25     2      ≤0.031
      Vibrio vulnificus                                           ATCC 27562   1                                                0.5      1        ≤0.031   0.063    ≤0.031   2        4        2      ≤0.031
      Yersinia enterocolitica                                     ATCC 9610    ≤0.031                                           0.125    0.063    0.063    1        0.125    0.25     0.25     2      0.063
      Yersinia pseudotuberculosis                                 ATCC 29833   0.5                                              0.25     0.063    ≤0.031   0.5      0.25     0.25     \>32     2      ≤0.031
  Gram-positive bacteria                                                                                                                                                                              
      Bacillus subtilis                                           ATCC 6633    32                                               4        1        0.063    0.25     4        2        8        0.25   ≤0.031
      Enterococcus faecalis                                       ATCC 29212   \>32                                             \>32     16       2        2        \>32     32       \>32     \>32   1
      Lactobacillus casei                                         ATCC 393     \>32                                             4        32       1        0.5      4        2        \>32     2      1
      Micrococcus luteus                                          ATCC 9341    4                                                0.5      ≤0.031   0.063    ≤0.031   0.5      0.5      \>32     1      2
      Staphylococcus aureus                                       ATCC 29213   32                                               8        8        0.125    1        8        32       \>32     2      0.5
      Streptococcus pneumoniae                                    ATCC 49619   2                                                0.5      ≤0.031   0.063    0.5      0.5      0.25     \>32     32     0.5
      Streptococcus pyogenes                                      ATCC 10389   1                                                0.125    ≤0.031   ≤0.031   0.063    0.125    0.125    \>32     16     0.125

CTX-M type β-lactamase producer.

Resistant to azithromycin.

Resistant to ceftriaxone.

VIM-10 and VEB-1 β-lactamase producer.

Resistant to tetracycline and trimethoprim-sulfamethoxazole.

MICs of cefiderocol (CFDC) were determined in iron-depleted cation-adjusted Mueller Hinton broth (ID-CAMHB), and those of other antibiotics were determined in CAMHB except when the following was used (see supplemental method 2): (i) CAMHB supplemented with 2.5 to 5.0% lysed horse blood for B. parapertussis, Streptococcus pneumoniae, Streptococcus pyogenes, Campylobacter jejuni, Neisseria meningitidis, and Lactobacillus casei, (ii) Haemophilus test medium broth for Haemophilus spp., or (iii) GC agar supplemented with 1% defined growth supplement for Neisseria gonorrhoeae, except for meropenem, which was determined on GC agar supplemented with 1% defined growth supplement without cysteine component. NT, not tested; CFDC, cefiderocol; CAZ, ceftazidime; CFPM, cefepime; MEPM, meropenem; PIPC-TAZ, piperacillin-tazobactam; CAZ-AVI, ceftazidime-avibactam; CFT-TAZ, ceftolozane-tazobactam; COL, colistin; AMK, amikacin; CPFX, ciprofloxacin. TAZ and AVI were at a fixed concentration of 4 μg/ml. MICs of PIPC-TAZ, CAZ-AVI, and CFT-TAZ are represented as the concentrations of PIPC, CAZ, and CFT, respectively.

###### 

MICs of cefiderocol and other antibiotics against anaerobic bacteria

  Organism                             Strain        MIC (μg/ml)[^*a*^](#T2F1){ref-type="table-fn"}                             
  ------------------------------------ ------------- ------------------------------------------------ -------- -------- ------- -------
  Gram-negative bacteria                                                                                                        
      Bacteroides fragilis             ATCC 25285    2                                                32       0.063    2       0.25
      Bacteroides thetaiotaomicron     ATCC 29741    \>32                                             \>32     0.125    16      1
      Fusobacterium mortiferum         ATCC 25557    \>32                                             \>32     0.25     2       0.5
      Fusobacterium necrophorum        ATCC 25286    ≤0.031                                           ≤0.031   ≤0.031   1       0.125
      Mobiluncus curtisii              ATCC 35241    1                                                0.25     ≤0.031   0.5     2
      Prevotella bivia                 ATCC 29303    \>32                                             \>32     0.25     32      1
      Prevotella intermedia            ATCC 25611    1                                                0.25     ≤0.031   0.5     0.5
      Prevotella melaninogenica        ATCC 25845    2                                                0.25     ≤0.031   1       0.5
      Veillonella parvula              ATCC 10790    32                                               1        0.125    0.125   2
  Gram-positive bacteria                                                                                                        
      Bifidobacterium bifidum          ATCC 29521    0.5                                              0.063    ≤0.031   8       4
      Clostridium difficile            ATCC 700057   \>32                                             \>32     1        8       0.125
      Clostridium perfringens          ATCC 13124    1                                                0.25     ≤0.031   0.25    0.5
      Collinsella aerofaciens          ATCC 25986    \>32                                             2        0.125    1       0.5
      Eubacterium limosum              ATCC 8486     0.5                                              ≤0.031   ≤0.031   1       0.125
      Finegoldia magna                 ATCC 29328    8                                                8        0.063    0.25    0.5
      Parvimonas micra                 ATCC 33270    1                                                0.125    ≤0.031   0.5     0.5
      Peptoniphilus asaccharolyticus   ATCC 14963    32                                               0.063    ≤0.031   0.5     0.5
      Peptostreptococcus anaerobius    ATCC 27337    8                                                0.5      0.25     1       0.25
      Propionibacterium acnes          ATCC 6919     8                                                0.5      ≤0.031   0.5     \>32

MICs were determined on brucella agar supplemented with hemin, vitamin K1, and laked sheep blood.

###### 

MIC~50~s and MIC~90~s of cefiderocol and other antibiotics against anaerobic bacteria

  Organism (no. of strains)[^*a*^](#T3F1){ref-type="table-fn"}   MIC~50~/MIC~90~ (μg/ml)[^*b*^](#T3F2){ref-type="table-fn"}                                        
  -------------------------------------------------------------- ------------------------------------------------------------ ----------- -------------- --------- -------------
  Bacteroides spp. (83)                                          \>32/\>32                                                    \>32/\>32   0.125/2        16/\>32   0.5/1
  Prevotella spp. (37)                                           32/\>32                                                      4/\>32      ≤0.031/0.125   1/\>32    0.5/2
  C. difficile (38)                                              \>32/\>32                                                    \>32/\>32   1/2            8/\>32    0.125/0.125

Bacteriodes spp. consisted of *B. caccae* (4 strains), B. fragilis (52), B. fragilis group (9), *B. ovatus* (2), *B. stercoris* (1), B. thetaiotaomicron (11), and B. vulgatus (4). Prevotella spp. consisted of *P. bivia* (11 strains), *P. buccae* (7), *P. disiens* (4), P. intermedia (10), P. melaninogenica (1), *P. oralis* (1), and Prevotella species (6).

MICs were determined on brucella agar supplemented with hemin, vitamin K1, and laked sheep blood.

Antibacterial activity against Gram-negative bacteria harboring various β-lactamases. {#sec2-2}
-------------------------------------------------------------------------------------

Cefiderocol exhibited potent *in vitro* activity against 33 strains of Gram-negative bacteria harboring various kinds of β-lactamases, including extended-spectrum β-lactamases (ESBLs) and carbapenemases ([Table 4](#T4){ref-type="table"}). The MICs of cefiderocol were 8 μg/ml or lower against all the test strains, including carbapenemase producers such as Klebsiella pneumoniae harboring NDM-1, KPC, or GES-4, P. aeruginosa harboring VIM or IMP-1, and A. baumannii harboring OXA-23 and/or OXA-51-like or OXA-58. Other tested antibiotics, including various classes of β-lactams, amikacin, and ciprofloxacin, showed less activity against most of these carbapenemase producers, with MICs of 16 μg/ml or more, while colistin showed MICs of 1 μg/ml or lower.

###### 

MICs of cefiderocol against Gram-negative bacteria harboring β-lactamases

  Organism        Strain         β-Lactamase(s)                                        MIC (μg/ml)[^*a*^](#T4F1){ref-type="table-fn"}                                                              
  --------------- -------------- ----------------------------------------------------- ------------------------------------------------ ------ ------- -------- ------ ------ ------ ------ ------ --------
  E. coli         SR34250        CTX-M-14, TEM-1                                       0.125                                            2      4       ≤0.031   2      0.25   0.5    0.25   2      32
  E. coli         SR34201        CTX-M-15, TEM-1                                       2                                                \>32   \>32    0.063    2      0.25   0.5    0.5    2      32
  E. coli         SR34241        CTX-M-27                                              1                                                8      8       ≤0.031   2      0.25   0.5    0.25   2      \>32
  E. coli         ATCC BAA-196   TEM-10                                                1                                                \>32   4       ≤0.031   8      2      2      0.25   8      0.25
  E. coli         ATCC BAA-198   TEM-26                                                0.5                                              \>32   4       ≤0.031   4      1      1      0.25   2      0.25
  K. pneumoniae   ATCC 51983     SHV-5                                                 0.5                                              \>32   2       0.063    2      0.25   1      0.5    2      ≤0.031
  K. pneumoniae   ATCC 700603    SHV-18                                                1                                                32     0.5     0.063    16     0.5    1      0.25   1      0.5
  K. pneumoniae   NUBL-KG502     GES-4                                                 0.25                                             \>32   16      16       32     16     \>32   0.25   32     0.063
  P. aeruginosa   SR24837        PER-1                                                 4                                                \>32   \>32    8        \>32   \>32   \>32   0.5    8      1
  K. pneumoniae   VA-360         KPC-2, TEM-1, SHV-11, SHV-12                          8                                                \>32   \>32    \>32     \>32   2      \>32   0.25   16     \>32
  K. pneumoniae   VA-375         KPC-3, TEM-1, SHV-11, SHV-14                          2                                                \>32   32      32       \>32   2      \>32   0.25   8      \>32
  E. coli         NUBL-24        IMP-1                                                 1                                                \>32   \>32    8        16     \>32   \>32   0.25   2      \>32
  P. aeruginosa   SR27060        IMP-1                                                 0.25                                             \>32   \>32    \>32     \>32   \>32   \>32   1      16     32
  A. baumannii    SBRKM-181      IMP-1                                                 0.125                                            \>32   \>32    32       32     \>32   \>32   0.5    16     0.5
  K. pneumoniae   SR08933        IMP-6                                                 0.125                                            \>32   \>32    32       4      \>32   \>32   0.5    1      32
  E. coli         IR5            NDM-1, CTX-M-15, OXA-9                                2                                                \>32   \>32    \>32     \>32   \>32   \>32   0.25   \>32   \>32
  K. pneumoniae   I1             NDM-1, SHV-12                                         2                                                \>32   \>32    32       \>32   \>32   \>32   8      \>32   \>32
  K. pneumoniae   KI2            NDM-1, OXA-1, CTX-M-15, CMY-6, TEM-1, SHV-28, OXA-9   4                                                \>32   \>32    \>32     \>32   \>32   \>32   0.25   \>32   \>32
  P. aeruginosa   AK54           VIM-2                                                 0.125                                            32     16      \>32     \>32   32     \>32   1      \>32   16
  P. aeruginosa   DM3355         VIM-6                                                 2                                                \>32   \>32    \>32     \>32   \>32   \>32   1      \>32   \>32
  P. aeruginosa   P0510          VIM-1                                                 0.5                                              32     32      \>32     \>32   32     \>32   1      \>32   16
  E. coli         SR09616        CMY-2                                                 0.125                                            \>32   1       0.063    32     0.25   4      0.5    2      0.25
  K. pneumoniae   NUBL-HKY327    CMY-19                                                1                                                \>32   \>32    0.063    \>32   \>32   \>32   0.25   16     ≤0.031
  K. pneumoniae   SR09603        CMY-8                                                 0.063                                            8      0.125   0.25     8      0.25   0.5    0.25   8      ≤0.031
  K. pneumoniae   SR09635        DHA                                                   0.125                                            \>32   0.125   0.125    \>32   0.25   1      0.25   0.5    0.5
  S. marcescens   SR36500        AmpC                                                  0.125                                            8      1       0.25     16     2      8      \>32   16     4
  P. aeruginosa   TESS           AmpC                                                  0.25                                             32     16      16       \>32   4      2      0.5    \>32   32
  A. baumannii    585            OXA-23                                                0.063                                            \>32   32      \>32     \>32   8      16     0.25   \>32   \>32
  A. baumannii    CHAR           OXA-58                                                1                                                \>32   32      16       \>32   \>32   \>32   16     \>32   \>32
  A. baumannii    NCTC 13303     OXA-26, OXA-51-like                                   0.5                                              \>32   \>32    \>32     \>32   \>32   \>32   0.5    \>32   \>32
  A. baumannii    NCTC 13422     OXA-51-like                                           0.5                                              \>32   \>32    8        \>32   \>32   \>32   0.5    \>32   \>32
  A. baumannii    NCTC 13424     OXA-23, OXA-51-like                                   ≤0.031                                           \>32   32      32       \>32   32     32     0.5    \>32   \>32
  K. pneumoniae   PLE            OXA-48                                                ≤0.031                                           1      2       2        \>32   0.25   1      0.25   2      \>32

MICs of cefiderocol were determined in iron-depleted cation-adjusted Mueller Hinton broth (ID-CAMHB), and those of other antibiotics were determined in CAMHB. CFDC, cefiderocol; CAZ, ceftazidime; CFPM, cefepime; MEPM, meropenem; PIPC-TAZ, piperacillin-tazobactam; CAZ-AVI, ceftazidime-avibactam; CFT-TAZ, ceftolozane-tazobactam; COL, colistin; AMK, amikacin; CPFX, ciprofloxacin. TAZ and AVI were at a fixed concentration of 4 μg/ml. MICs of PIPC-TAZ, CAZ-AVI, and CFT-TAZ are represented as the concentrations of PIPC, CAZ and CFT, respectively.

Affinity for penicillin-binding proteins, morphological changes, and time-kill. {#sec2-3}
-------------------------------------------------------------------------------

The affinities (50% inhibitory concentrations \[IC~50~s\]) of cefiderocol for PBPs of E. coli NIHJ JC-2, K. pneumoniae SR22291, P. aeruginosa ATCC 27853, and A. baumannii ATCC 17978 were determined ([Table 5](#T5){ref-type="table"}). The IC~50~s of cefiderocol against PBP3 of E. coli NIHJ JC-2, K. pneumoniae SR22291, P. aeruginosa ATCC 27853, and A. baumannii ATCC 17978 were 0.04, 0.062, 0.06, and 0.67 μg/ml, respectively, which were lower than those of ceftazidime, indicating a higher affinity of cefiderocol for PBP3 than that of ceftazidime. Other than its affinity for PBP3, cefiderocol had an affinity for PBP2 of K. pneumoniae SR22291 as ceftazidime did (IC~50~s of cefiderocol and ceftazidime were 0.063 and 0.41 μg/ml, respectively), and cefiderocol also had an affinity for PBP1a of P. aeruginosa ATCC 27853 as ceftazidime did (IC~50~s of cefiderocol and ceftazidime were 0.85 and 3.62 μg/ml, respectively). Morphological changes of these four bacteria were examined by phase-contrast microscopy after exposure to cefiderocol (see Fig. S1 and S2 in the supplemental material). Filamentous cells were observed in all the test strains after exposure to cefiderocol, similar to what was observed after exposure to ceftazidime. In the time-kill study with the four strains E. coli NIHJ JC-2, K. pneumoniae SR22291, P. aeruginosa ATCC 27853, and A. baumannii ATCC 17978, cefiderocol reduced the bacterial counts in a manner similar to that of ceftazidime after exposure at 1, 4, or 16 times the MIC, and the killing rates were similar between 4 times and 16 times the MIC ([Fig. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

###### 

Affinity of cefiderocol and ceftazidime for penicillin-binding proteins of E. coli NIHJ JC-2, K. pneumoniae SR22291, P. aeruginosa ATCC 27853, and A. baumannii ATCC 17978

  PBP     IC~50~ (μg/ml)                                                                                                      
  ------- --------------------------------------- ------ ------- ------ ------ ------ --------------------------------------- ------
  PBP1a   3.80                                    \>4    2.80    1.50   0.85   3.62   1.05                                    0.91
  PBP1b   3.37                                    \>4    3.50    2.30   \>4    \>4                                            
  PBP2    2.12                                    \>4    0.063   0.41   \>4    \>4    2.31                                    \>64
  PBP3    0.04                                    0.45   0.062   0.22   0.06   0.09   0.67                                    1.78
  PBP4    NC[^*b*^](#T5F2){ref-type="table-fn"}   \>1    0.28    3.60   \>4    \>4    ND[^*c*^](#T5F3){ref-type="table-fn"}   ND

The IC~50~s cannot be divided into separate values for PBP1a and PBP1b.

NC, not calculated. Cefiderocol inhibited 63% of PBP4 at 4 μg/ml, but the sigmoid curve did not fit and the IC~50~ cannot be calculated.

ND, not detected.

![Bactericidal activities of cefiderocol (a and c) and ceftazidime (b and d) against E. coli NIHJ JC-2 (a and b) and K. pneumoniae SR22291 (c and d). ID-CAMHB and CAMHB were used for cefiderocol and ceftazidime, respectively, as the test media.](zac0011867790001){#F1}

![Bactericidal activities of cefiderocol (a and c) and ceftazidime (b and d) against P. aeruginosa ATCC 27853 (a and b) and A. baumannii ATCC 17978 (c and d). ID-CAMHB and CAMHB were used for cefiderocol and ceftazidime, respectively, as the test media.](zac0011867790002){#F2}

Effects of transposon insertion into or deletions of genes relating to outer membrane permeability on the activities. {#sec2-4}
---------------------------------------------------------------------------------------------------------------------

The effects of the deficiency of iron transporters were examined using P. aeruginosa and E. coli ([Table 6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}). The MICs of cefiderocol against all the test P. aeruginosa PAO1 derivative mutant strains which have a transposon (Tn) insertion in the genes of iron transporters, including major siderophore receptors for pyoverdine (*fpvA* and *fpvB*), pyochelin (*fptA*), and enterobactin (*pirA*), ranged from 0.063 to 0.125 μg/ml, equivalent to the MIC against the parent strain PAO1, with the exception of the MICs against the strains having a Tn insertion in the probable iron transport receptor gene *piuA* ([Table 6](#T6){ref-type="table"}). The MIC of cefiderocol increased to 2 μg/ml (PW8599) after Tn insertion into *piuA*, which was complemented by the introduction of wild-type PiuA (SR-L00252). MICs of ceftazidime ranged from 1 to 2 μg/ml against all the tested strains with a Tn insertion in iron transporter-related genes as well as the parent strain PAO1. The MIC of cefiderocol against E. coli BW25113 with deletion of iron transporter gene *cirA* or *fiu* was 0.063 or 0.125 μg/ml, within 2-fold of that against the parent strain, whereas the MIC of cefiderocol increased 16-fold by the double knockout of *cirA* and *fiu* ([Table 7](#T7){ref-type="table"}).

###### 

Effects of transposon insertion into genes for iron transporters, efflux pump, and porin on the activities of cefiderocol against P. aeruginosa PAO1

  Strain      Description[^*a*^](#T6F1){ref-type="table-fn"}   MIC (μg/ml)[^*b*^](#T6F2){ref-type="table-fn"}                      
  ----------- ------------------------------------------------ ------------------------------------------------ --- ----- -------- ------
  PAO1                                                         0.125                                            2   1     0.125    4
  PW1781      *mexB* (Tn)                                      0.063                                            1   1     0.063    0.25
  PW1783      *oprM* (Tn)                                      0.063                                            1   1     ≤0.031   0.25
  PW1776      *mexR* (Tn)                                      0.25                                             8   1     0.5      16
  PW7066      *nalD* (Tn)                                      0.25                                             8   1     0.5      16
  PW2742      *oprD* (Tn)                                      0.25                                             1   8     0.25     4
  PW1861      *fiuA* (Tn)                                      0.063                                            2   ---   ---      ---
  PW2689      *pirA* (Tn)                                      0.063                                            2   ---   ---      ---
  PW3399      *pfuA* (Tn)                                      0.063                                            2   ---   ---      ---
  PW4366      *feuA* (*cirA*) (Tn)                             0.063                                            2   ---   ---      ---
  PW5036      *fpvA* (Tn)                                      0.063                                            2   ---   ---      ---
  PW5144      *foxA* (*optS*) (Tn)                             0.125                                            2   ---   ---      ---
  PW5503      *pfeA* (Tn)                                      0.063                                            1   ---   ---      ---
  PW7590      *fecA* (Tn)                                      0.063                                            1   ---   ---      ---
  PW8065      *fpvB* (Tn)                                      0.063                                            2   ---   ---      ---
  PW8161      *fptA* (Tn)                                      0.125                                            2   ---   ---      ---
  PW8599      *piuA* (Tn)                                      2                                                2   ---   ---      ---
  SR-L00016   *piuA* (Tn) and *pirA* (deletion)                2                                                2   ---   ---      ---
  SR-L00197   *piuA* (Tn)/pMMB67HE-Gm                          2                                                1   ---   ---      ---
  SR-L00252   *piuA* (Tn)/pMMB67HE-Gm-piuA                     0.063                                            1   ---   ---      ---

Tn, transposon insertion.

---, not tested. MICs of cefiderocol were determined in ID-CAMHB, and those of references were determined in CAMHB.

###### 

Effects of deletions of genes for iron transporters and porins on the activities of cefiderocol against E. coli BW25113 and K. pneumoniae NVT2001S

  Strain                      Description                                                 MIC (μg/ml)[^*a*^](#T7F1){ref-type="table-fn"}           
  --------------------------- ----------------------------------------------------------- ------------------------------------------------ ------- -------
  E. coli                                                                                                                                          
      BW25113                 Derivative strain of K-12                                   0.063                                            0.25    
      BW25113 *ΔcirA*         *cirA* deletion strain of BW25113                           0.063                                            0.25    
      BW25113 *Δfiu*          *fiu* deletion strain of BW25113                            0.125                                            0.125   
      BW25113 *ΔcirA Δfiu*    *cirA* and *fiu* deletion strain of BW25113                 1                                                0.25    
  K. pneumoniae                                                                                                                                    
      NVT2001S                Streptomycin-resistant isolate of clinical strain NVT2001   0.031                                            0.125   0.016
      NVT2001S *ΔompK35*      *ompK35* deletion strain of NVT2001S                        0.125                                            0.5     0.031
      NVT2001S *ΔompK36*      *ompK36* deletion strain of NVT2001S                        0.063                                            0.25    0.031
      NVT2001S *ΔompK35/36*   *ompK35* and *ompK36* deletion strain of NVT2001S           0.063                                            0.5     0.125

MICs of cefiderocol were determined in ID-CAMHB, and those of references were determined in CAMHB.

The MICs of cefiderocol against PAO1 derivative mutant strains which have a Tn insertion in the genes of multidrug efflux pump MexAB-OprM, its transcriptional regulator, and porin OprD, which are involved in β-lactam resistance, were examined ([Table 6](#T6){ref-type="table"}). MICs of aztreonam against the strains with a Tn insertion in either *mexB* (PW1781) or *oprM* (PW1783), which lost the function of the MexAB-OprM efflux pump, were 16-fold lower than that against PAO1, while the decreases in cefiderocol MICs due to a Tn insertion were 2- or 4-fold. The MIC of cefiderocol was also determined against PW1781 and PW1783 in cation-adjusted Mueller-Hinton broth (CAMHB), which contains ferric iron, and the cefiderocol MICs were 0.125 and 0.063 μg/ml, respectively, which were 2- or 4-fold lower, respectively, than that against PAO1, which was 0.25 in CAMHB. The MICs of ceftazidime, aztreonam, and ciprofloxacin against the strains with a Tn insertion in either *mexR* (PW1776) or *nalD* (PW7066), which leads to overexpression of the MexAB-OprM efflux pump, were 4-fold higher than that against PAO1, while the increases in cefiderocol MICs due to a Tn insertion were within 2-fold. The MIC of cefiderocol was also determined against PW1776 and PW7066 in CAMHB, and the increases in cefiderocol MICs were also 2-fold compared to that against PAO1. Against the strain with a Tn insertion in *oprD*, imipenem showed an 8-fold higher MIC than against the parent strain, while the increases in MIC of cefiderocol and other test antibiotics were within 2-fold.

The MIC of cefiderocol was determined against K. pneumoniae NVT2001S and its derivative mutant strains, which were deficient in porin *ompK35* and/or *ompK36*, which are involved in resistance to various classes of β-lactam antibiotics, including carbapenems ([Table 7](#T7){ref-type="table"}). The MIC of meropenem against the double deletion mutant strain was 8-fold higher than that against the parental strain NVT2001S, whereas the increases in MICs of cefiderocol and ceftazidime against strains with deletion of *ompK35* and/or *ompK36* were 2- to 4-fold that against the parental strain.

DISCUSSION {#sec3}
==========

In comparison to carbapenem antibiotics, cefiderocol has more potent *in vitro* activity against a broad range of Gram-negative bacteria, including carbapenem-resistant strains of Enterobacteriaceae and nonfermenting bacteria that produce carbapenemases as well as ESBLs and class C β-lactamases, but weaker activity against Gram-positive bacteria and anaerobic bacteria. Cefiderocol has an antibacterial spectrum that is significantly different from that of carbapenem antibiotics, which have been mainly used for the treatment of Gram-negative bacterial infections. The reason for this unique antibacterial spectrum is the active ferric iron uptake by the siderophore, which is observed only in aerobic Gram-negative bacteria. The detailed mode of action on the activity against some of the strains or species among Gram-positives and anaerobic bacteria has not been sufficiently observed. The global surveillance studies of cefiderocol, SIDERO-WT-2014, using recent clinical isolates (*n* = 9,205) against Enterobacteriaceae and nonfermenting bacteria such as P. aeruginosa, A. baumannii, and S. maltophilia, including MDR strains, and other studies to evaluate the antibacterial activity of cefiderocol against well-characterized carbapenem-resistant Gram-negative pathogens have shown that cefiderocol also has potent activity against these problematic Gram-negative pathogens ([@B10][@B11][@B12]).

This study revealed that the antibacterial action of cefiderocol is to inhibit mainly PBP3 of Enterobacteriaceae and nonfermenting bacteria, resulting in morphological changes of filamentous cells, similar to the action of ceftazidime. Although the impact of the differences in PBP3 affinity on the *in vitro* activities of cefiderocol and ceftazidime is not clear, the antibacterial activity of cefiderocol determined by the time-kill experiment was similar to that of ceftazidime. The key features of cefiderocol are its active uptake mechanisms by Gram-negative bacteria under iron-depleted conditions and its improved stability to various types of β-lactamases reported previously ([@B15]). In this study, we showed that PiuA is one of the iron transporters of P. aeruginosa that is responsible for the active transport of cefiderocol into bacterial cells resulting in the activity of cefiderocol, as is the case for MC-1 ([@B16]). However, the MIC results also showed that PirA, which was reported to be one of the iron transporters responsible for the activity of MC-1 ([@B16]), did not contribute to the *in vitro* activity of cefiderocol. Moreover, this study demonstrated the contribution of both *cirA* and *fiu* of E. coli, which has been reported to be involved in the monomeric catechols and whose production is regulated by the availability of ferric iron, to the *in vitro* activity of cefiderocol ([@B17]).

The MIC results with mutant strains showed that the effect of the deficiency of the porin OmpK35/36 of K. pneumoniae, which is reported to be one of the resistance determinants coordinated with various β-lactamases against carbapenems ([@B18], [@B19]), on the activity of cefiderocol was not significant, which may also contribute to the potent activity of cefiderocol against such carbapenem-resistant K. pneumoniae strains. In terms of the efflux pump MexAB-OprM of P. aeruginosa, the decrease in the MIC of cefiderocol against the strains with a deficient efflux pump indicates that cefiderocol could be a substrate for the efflux pump MexAB-OprM. However, the overproduction of the efflux pump increased the cefiderocol MIC only slightly, even under the condition with ferric iron in the medium, in which the function of active transport for cefiderocol is weak; this indicates that the effect of the overproduction on the activity of cefiderocol should be limited and that cefiderocol is not taken into bacterial cells faster than it is extruded from the bacterial cells by the efflux pump. On the other hand, it has been reported that BAL30072 is a substrate for the efflux pumps MexAB-OprM and MexEF-OprN ([@B20]) and that MC-1 is a substrate for the efflux pump MexAB-OprM ([@B16]). Those reports suggest that cefiderocol has different profiles of transport into P. aeruginosa with other siderophore-conjugated β-lactams. These studies are limited in clarifying and understanding the differences in the mechanisms of action of cefiderocol and other siderophore-conjugated β-lactams, and further detailed studies are required.

In summary, this study showed that cefiderocol has potent *in vitro* activity against a broad range of aerobic Gram-negative bacteria, including MDR strains, and that the antibacterial activity of cefiderocol is based mainly on the inhibition of PBP3. This study also revealed that iron transporters such as PiuA of P. aeruginosa and CirA and Fiu of E. coli are involved in the permeation of cefiderocol into bacterial cells. The characteristics of cefiderocol indicate that cefiderocol may be a promising option for the treatment of infections caused by a broad range of Gram-negative pathogens, including MDR Enterobacteriaceae and MDR nonfermenting bacteria.

MATERIALS AND METHODS {#sec4}
=====================

Bacterial strains. {#sec4-1}
------------------

A number of type strains were obtained from the American Type Culture Collection (Manassa, VA), the National Collection of Type Cultures (Salisbury, United Kingdom), and the National Institute of Technology and Evaluation Biological Resource Center (Tokyo, Japan). A number of clinical strains were kindly provided by the Bicêtre Hospital (Le Kremlin-Bicêtre, France), Singapore General Hospital (Singapore), and GlaxoSmithKline plc (Middlesex, United Kingdom). Other test strains were obtained from various hospitals, mainly in Japan. Species-appropriate quality control (QC) strains, which were obtained from the ATCC, were used as described in Clinical and Laboratory Standards Institute (CLSI) guidelines ([@B21][@B22][@B24]). Transposon (Tn) insertion mutant strains of P. aeruginosa PAO1 were kindly provided by the University of Washington ([@B25]). A PAO1 derivative of SR-L00016 was constructed from PW8599 by deletion of the *pirA* gene according to the method described by Alexeyev et al. and Schweizer et al. ([@B26], [@B27]). The PiuA expression plasmid was constructed by using an In-Fusion HD cloning kit (TaKaRa Bio, Inc., Shiga, Japan) with pMMB67HE-Gm, and PW8599 was transformed with the plasmid to obtain SR-L00252. The *cirA* and/or *fiu* deletion mutants of E. coli BW25113 were constructed according to the methods described by Datsenko et al. ([@B28]). Detailed procedures for constructing the plasmid and recombinant strains are described in the supplemental material (see Method S1). K. pneumoniae NVT2001S and its *ompK35* and/or *ompK36* deletion mutants were kindly provided by the National Health Research Institutes in Taiwan.

Antibiotics. {#sec4-2}
------------

Cefiderocol, ceftolozane, and avibactam were synthesized at the research laboratories of Shionogi & Co., Ltd. (Osaka, Japan). Commercial-grade antibiotics were obtained as follows: ceftazidime, tazobactam, amikacin, and aztreonam from Chem-Impex International, Inc. (Wood Dale, IL); cefepime and metronidazole from U.S. Pharmacopeia (Rockville, MD); meropenem, colistin, and gentamicin from Wako Pure Chemical Industries, Ltd. (Osaka, Japan); and ciprofloxacin and piperacillin from LKT Laboratories, Inc. (St. Paul, MN).

MIC. {#sec4-3}
----

MICs were determined by using broth microdilution or agar dilution according to the CLSI ([@B21][@B22][@B24]), except for the MIC for Bordetella parapertussis, which was determined by the method described by Mortensen and Rodgers ([@B29]). For the determination of cefiderocol MIC, iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) was prepared as previously described and used according to the recommendations of the CLSI ([@B30]), except for the cases that are required to determine MICs under specific conditions (Method S2). The quality control MIC ranges of cefiderocol approved by the CLSI were 0.06 to 0.5 μg/ml for both E. coli ATCC 25922 and P. aeruginosa ATCC 27853 ([@B31]). For anaerobic bacteria, brucella agar (Becton, Dickinson and Company, NJ) supplemented with hemin, vitamin K1, and laked sheep blood was used. For recombinant strains, test medium was supplemented with 10 μg/ml of gentamicin and/or 0.1 mM IPTG (isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside) (Wako Pure Chemical Industries) when required.

Affinity for penicillin-binding proteins. {#sec4-4}
-----------------------------------------

The affinities of cefiderocol and ceftazidime for PBPs of E. coli NHIJ JC-2, K. pneumoniae SR22291, and P. aeruginosa ATCC 27853 were determined by using benzylpenicillin \[benzyl-^14^C\]potassium (American Radiolabeled Chemicals, Inc., St. Louis, MO) as described by Spratt ([@B32]). For A. baumannii ATCC 17978, the method using Bocillin FL penicillin sodium salt (Life Technologies, Inc., Carlsbad, CA) reported by Vashist et al. ([@B33]) was used. Detailed procedures are described in the supplemental material (Method S3).

Morphological observation. {#sec4-5}
--------------------------

A bacterial suspension of the log-phase bacteria was smeared on compound-containing thin-layer Mueller-Hinton agar (Becton, Dickinson and Company, NJ) coated on a glass slide. After incubation at 35°C for 4 to 6 h, morphological changes of bacterial cells were observed with Leica DM2500 microscopy (Leica, Germany). Detailed procedures are described in the supplemental material (Method S4).

Time-kill study. {#sec4-6}
----------------

An overnight culture of the test strain was diluted into fresh medium to yield an inoculum of approximately 10^6^ CFU/ml. The ID-CAMHB and CAMHB media were used for cefiderocol and ceftazidime, respectively. Concentrations of antibiotics were 0 (control), 0.25, 1, 4, or 16 times the MIC. Incubation was performed at 35°C, and the sampling times were 2, 4, and 6 h after initiation of incubation. MICs against E. coli NIHJ JC-2, K. pneumoniae SR22291, P. aeruginosa ATCC 27853, and A. baumannii ATCC 17978 were 0.25, 0.008, 0.063 and 0.016 μg/ml, respectively, for cefiderocol (ID-CAMHB) and 0.25, 0.063, 1 and 4 μg/ml, respectively, for ceftazidime (CAMHB).

Supplementary Material
======================

###### Supplemental material

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.01454-17>.
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